Caribou Biosciences Inc is a biotechnology company focused on developing transformative cellular therapies using its proprietary CRISPR genome-editing technology
The company leverages its innovative platform to create engineered immune cells for the treatment of various cancers and other serious diseases. By harnessing the power of CRISPR, Caribou aims to enhance the precision and effectiveness of therapies, ultimately improving patient outcomes and advancing the field of genetic medicine.
RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences, and Corbus Pharmaceuticals with key 2024 data readouts and trials.
U.S. stocks traded higher toward the end of trading, with the S&P 500 index gaining over 1% on Tuesday. The Dow traded up 0.74% to 39,057.10 while the NASDAQ rose 1.41% to 16,245.83. The S&P 500 also rose, gaining, 1.10% to 5,174.28.
Gainers Carbon Revolution Public Limited (NASDAQCREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge Capital Acquisition Corp.
